Raj Bhatia, MD
Pulmonary Disease · Oxnard
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 36 years
- Graduated 1990
Offices
3 locations · West Coast Critical Care Specialists, Inc. · Gila River Health Care Corporation
Hospitals listed: Huhu Kam Memorial Hospital · St Johns Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhatia’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A61991 · Current
Licensed to practise in California · since 1997 · expires 2027-04-30 · University of Poona, Pravara Rural Hospital and Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Huhu Kam Memorial HospitalSacaton, AZCritical Access Hospital · Government - Federal · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- St Johns Regional Medical CenterOxnard, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.06 (90.32 to 169.81) · 120 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.404, Oct 2024 – Sep 2025
See every measure and the patient survey for St Johns Regional Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.06 (90.32 to 169.81) · 120 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.404 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.8 (0 to 1.75) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.56 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.7 · 279 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 580 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 654 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,404 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 8,124 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.39) · 8,331 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.92 (1.89 to 5.95) · 1,414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.17 (0.6 to 3.75) · 412 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.94 (0.46 to 3.43) · 1,361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.75 (0.73 to 12.78) · 439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.94 (3.39 to 10.49) · 383 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.67) · 7,172 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 88 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.236 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.331 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.571 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.737 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 336 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 715 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -8.1 · 284 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -9.1 · 674 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.9 · 670 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (5.2 to 8.9) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (8.6 to 13.5) · 428 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 98 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 196 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.5 to 18.8) · 247 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 486 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,151 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$146,732
Medicare paid this office $146,732 for 657 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 96 | $42,721 | $423 |
| Sleep study in sleep lab (6 years or older) | 147 | $35,844 | $244 |
| Return visit (30+ min) | 111 | $19,486 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $10,196 | $103 |
| Short return visit (20+ min) | 87 | $8,558 | $82 |
See all 13 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 96 | $42,721 | $423 |
| Sleep study in sleep lab (6 years or older) | 147 | $35,844 | $244 |
| Return visit (30+ min) | 111 | $19,486 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $10,196 | $103 |
| Short return visit (20+ min) | 87 | $8,558 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,617 | $152 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 21 | $4,551 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,161 | $69 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 67 | $2,662 | $40 |
| New patient visit (45+ min) | 17 | $2,595 | $153 |
| Sleep study including heart rate, breathing, and sleep time | 76 | $2,592 | $34 |
| New patient visit (30+ min) | 11 | $1,127 | $102 |
| Test for exercise-induced lung stress | 13 | $473 | $32 |
Who their Medicare patients are
657 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 9% · Women 51% · Also on Medicaid 27% · Health risk score 1.68. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 37% · COPD 31% · Depression 28% · Atrial fibrillation 27% · Heart failure 26% · Chronic kidney disease 26% · Cancer 17% · Stroke 13% · Dementia 7%.
The office billed $558,359, Medicare allowed $183,933 and paid $146,732; for 1,047 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 657 | 1,047 | 72 | 1.68 | $558,359 | $146,732 |
| 2023 | 419 | 820 | 76 | 2.36 | $424,456 | $112,242 |
| 2022 | 758 | 1,454 | 73 | 1.77 | $605,220 | $154,188 |
| 2021 | 726 | 1,235 | 73 | 1.79 | $481,431 | $143,438 |
| 2020 | 869 | 1,650 | 74 | 2.12 | $601,302 | $199,676 |
| 2019 | 1,028 | 2,012 | 73 | 2.09 | $890,614 | $280,650 |
| 2018 | 1,004 | 2,289 | 73 | 2.08 | $809,414 | $312,193 |
| 2017 | 858 | 2,598 | 73 | 2.23 | $861,771 | $263,143 |
| 2016 | 516 | 1,965 | 73 | 2.13 | $687,058 | $209,277 |
| 2015 | 573 | 1,794 | 72 | 2.23 | $639,890 | $215,184 |
| 2014 | 501 | 1,570 | 74 | 2.19 | $558,034 | $191,228 |
| 2013 | 596 | 2,292 | 74 | 2.29 | $674,798 | $239,518 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 68 | $31,776 | $448 |
| Sleep study in sleep lab (6 years or older) | 34 | $16,668 | $490 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $14,925 | $100 |
| Short return visit (20+ min) | 111 | $12,703 | $75 |
| Return visit (30+ min) | 71 | $11,064 | $105 |
| Critical care, first 30-74 minutes | 43 | $9,999 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $3,336 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,601 | $130 |
| New patient visit (45+ min) | 14 | $2,025 | $145 |
| New patient visit (30+ min) | 22 | $1,723 | $78 |
| Test to examine how well the lungs exchange gases | 23 | $1,052 | $46 |
| Test to determine lung volumes using sensors | 23 | $958 | $42 |
| Test for exercise-induced lung stress | 18 | $624 | $30 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | $607 | $26 |
| Test to measure expiratory airflow and volume | 16 | $396 | $25 |
2022: 17 services
| Sleep study in sleep lab (6 years or older) | 115 | $28,764 | $250 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 86 | $26,896 | $302 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $18,953 | $86 |
| Return visit (30+ min) | 115 | $18,897 | $104 |
| Short return visit (20+ min) | 124 | $12,720 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,750 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $7,640 | $60 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 140 | $5,296 | $38 |
| New patient visit (45+ min) | 37 | $5,072 | $137 |
| Critical care, first 30-74 minutes | 14 | $3,299 | $183 |
| Telephone medical discussion with physician, 11-20 minutes | 45 | $3,132 | $63 |
| New patient visit (30+ min) | 29 | $2,403 | $83 |
| Test to examine how well the lungs exchange gases | 41 | $2,115 | $52 |
| Test to determine lung volumes using sensors | 40 | $1,902 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $1,392 | $34 |
| Test for exercise-induced lung stress | 17 | $624 | $30 |
| Test to measure expiratory airflow and volume | 26 | $624 | $24 |
2021: 18 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 86 | $31,093 | $342 |
| Sleep study in sleep lab (6 years or older) | 92 | $28,354 | $308 |
| Return visit (30+ min) | 103 | $14,794 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $12,514 | $81 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 195 | $10,912 | $56 |
| Short return visit (20+ min) | 108 | $10,496 | $78 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | $5,587 | $95 |
| Telephone medical discussion with physician, 11-20 minutes | 73 | $5,561 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,780 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,497 | $62 |
| New patient visit (45+ min) | 22 | $3,198 | $145 |
| Critical care, first 30-74 minutes | 14 | $2,724 | $182 |
| Long return visit (40+ min) | 15 | $2,395 | $133 |
| New patient visit (30+ min) | 19 | $1,699 | $89 |
| Test to examine how well the lungs exchange gases | 21 | $1,135 | $54 |
| Test to measure expiratory airflow and volume | 37 | $972 | $26 |
| Test to determine lung volumes using sensors | 20 | $960 | $48 |
| Test for exercise-induced lung stress | 13 | $420 | $30 |
2020: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 228 | $40,234 | $92 |
| Sleep study in sleep lab (6 years or older) | 104 | $30,058 | $286 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 153 | $27,562 | $174 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 67 | $26,561 | $369 |
| Return visit (30+ min) | 154 | $22,059 | $88 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 172 | $14,102 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $9,106 | $63 |
| Critical care, first 30-74 minutes | 37 | $8,929 | $194 |
| Telephone medical discussion with physician, 11-20 minutes | 76 | $6,077 | $68 |
| New patient visit (45+ min) | 26 | $3,711 | $143 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,147 | $98 |
| Short return visit (20+ min) | 26 | $1,735 | $60 |
| Test for exercise-induced lung stress | 16 | $545 | $30 |
2019: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 196 | $75,729 | $352 |
| Sleep study in sleep lab (6 years or older) | 295 | $62,650 | $212 |
| Return visit (30+ min) | 261 | $48,569 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 201 | $37,659 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $18,468 | $162 |
| Critical care, first 30-74 minutes | 43 | $11,570 | $181 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 64 | $4,654 | $73 |
| New patient visit (45+ min) | 31 | $4,435 | $143 |
| Short return visit (20+ min) | 45 | $3,222 | $64 |
| New patient visit (30+ min) | 24 | $2,038 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,790 | $62 |
| Long return visit (40+ min) | 14 | $1,687 | $121 |
| Test for exercise-induced lung stress | 29 | $1,008 | $29 |
| Test to measure expiratory airflow and volume | 26 | $824 | $32 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $731 | $52 |
2018: 18 services
| Sleep study in sleep lab (6 years or older) | 319 | $79,160 | $247 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 193 | $76,019 | $369 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 213 | $48,868 | $86 |
| Return visit (30+ min) | 221 | $39,246 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 141 | $24,954 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 91 | $10,821 | $60 |
| Critical care, first 30-74 minutes | 25 | $6,217 | $207 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 69 | $5,389 | $78 |
| Short return visit (20+ min) | 75 | $5,163 | $59 |
| New patient visit (30+ min) | 35 | $2,883 | $82 |
| New patient visit (45+ min) | 18 | $2,534 | $141 |
| Long return visit (40+ min) | 12 | $1,499 | $125 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,364 | $124 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,169 | $106 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $973 | $49 |
| Test to measure expiratory airflow and volume | 21 | $690 | $33 |
| Test for exercise-induced lung stress | 16 | $505 | $30 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 15 | $1 | None |
2017: 20 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 144 | $57,763 | $380 |
| Sleep study in sleep lab (6 years or older) | 167 | $50,862 | $303 |
| Return visit (30+ min) | 206 | $37,048 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 141 | $28,824 | $88 |
| Critical care, first 30-74 minutes | 48 | $16,182 | $184 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $15,665 | $168 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 202 | $11,068 | $52 |
| Test to examine how well the lungs exchange gases | 208 | $10,341 | $49 |
| Test to determine lung volumes using sensors | 208 | $9,831 | $46 |
| New patient visit (30+ min) | 60 | $5,243 | $87 |
| Short return visit (20+ min) | 81 | $5,066 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $3,705 | $60 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,427 | $110 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,392 | $116 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 17 | $1,337 | $79 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,029 | $94 |
| Test to measure rate of airflow | 17 | $448 | $26 |
| Inhalation treatment for airway obstruction or sputum production | 25 | $428 | $17 |
| Test to measure largest amount of air breathed in an out | 16 | $376 | $23 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 103 | $11 | None |
2016: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 90 | $57,670 | $571 |
| Sleep study in sleep lab (6 years or older) | 79 | $43,896 | $549 |
| Return visit (30+ min) | 121 | $27,158 | $89 |
| Measurement of lung stretching capacity | 190 | $14,519 | $74 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 203 | $11,404 | $54 |
| Test to examine how well the lungs exchange gases | 196 | $9,863 | $49 |
| Test to determine lung volumes using sensors | 199 | $9,527 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $9,356 | $86 |
| Critical care, first 30-74 minutes | 28 | $7,553 | $184 |
| Short return visit (20+ min) | 66 | $5,112 | $59 |
| New patient visit (30+ min) | 47 | $3,940 | $84 |
| Inhalation treatment for airway obstruction or sputum production | 153 | $2,642 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,211 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,452 | $61 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 141 | $20 | None |
2015: 13 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 88 | $56,010 | $572 |
| Sleep study in sleep lab (6 years or older) | 85 | $45,876 | $540 |
| Return visit (30+ min) | 130 | $25,709 | $91 |
| Measurement of lung stretching capacity | 208 | $15,695 | $73 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 224 | $12,309 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $11,574 | $86 |
| Test to examine how well the lungs exchange gases | 215 | $10,865 | $49 |
| Test to determine lung volumes using sensors | 223 | $10,461 | $46 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,382 | $168 |
| Short return visit (20+ min) | 60 | $4,764 | $60 |
| Critical care, first 30-74 minutes | 20 | $4,602 | $184 |
| New patient visit (30+ min) | 43 | $3,733 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,442 | $59 |
2014: 14 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 81 | $57,484 | $587 |
| Sleep study in sleep lab (6 years or older) | 63 | $36,636 | $547 |
| Return visit (30+ min) | 129 | $21,931 | $90 |
| Measurement of lung stretching capacity | 193 | $14,649 | $75 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 196 | $10,370 | $51 |
| Test to examine how well the lungs exchange gases | 191 | $9,500 | $49 |
| Test to determine lung volumes using sensors | 194 | $8,963 | $45 |
| Short return visit (20+ min) | 91 | $6,327 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $5,038 | $85 |
| Critical care, first 30-74 minutes | 21 | $4,998 | $185 |
| Long return visit (40+ min) | 18 | $3,827 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $3,012 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,882 | $170 |
| New patient visit (30+ min) | 31 | $2,720 | $88 |
2013: 19 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 70 | $42,699 | $601 |
| Sleep study in sleep lab (6 years or older) | 57 | $32,887 | $577 |
| Return visit (30+ min) | 181 | $31,178 | $88 |
| Short return visit (20+ min) | 214 | $20,371 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $15,811 | $163 |
| Critical care, first 30-74 minutes | 50 | $14,392 | $180 |
| Measurement of lung stretching capacity | 171 | $13,744 | $79 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 177 | $11,452 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $11,419 | $84 |
| Test to examine how well the lungs exchange gases | 171 | $9,738 | $56 |
| Test to determine lung volumes using sensors | 171 | $9,219 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $6,505 | $58 |
| New patient visit (45+ min) | 40 | $5,087 | $127 |
| Long return visit (40+ min) | 32 | $4,511 | $116 |
| New patient visit (30+ min) | 29 | $2,558 | $88 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 18 | $1,586 | $88 |
| Exam of lung airways using an endoscope | 11 | $1,344 | $122 |
| Test to measure expiratory airflow and volume | 27 | $955 | $32 |
| Test to measure oxygen level in blood using ear or finger device | 100 | $303 | $3 |
Medicaid work
$44,792 in 2024
Medicaid paid $44,792 for 159 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 65 | $32,786 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 12 | $8,315 |
| Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time | 12 | $1,864 |
| SBSQ NURSING FACILITY CARE MOD MDM 30 MINUTES | 70 | $1,826 |
| 2024 | 159 | 4 | 39 | $44,792 |
| 2023 | 125 | 2 | 16 | $78,279 |
| 2022 | 182 | 4 | 50 | $22,919 |
| 2021 | 340 | 7 | 33 | $69,931 |
| 2020 | 476 | 6 | 36 | $61,422 |
| 2019 | 534 | 4 | 41 | $87,555 |
| 2018 | 614 | 7 | 29 | $50,005 |
See the largest Medicaid services in earlier years
2023
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 84 | $50,967 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 41 | $27,313 |
2022
| Return visit (30+ min) | 63 | $7,962 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 12 | $7,169 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 94 | $5,743 |
| New patient visit (45+ min) | 13 | $2,044 |
2021
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 53 | $30,426 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 27 | $17,614 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 122 | $6,737 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 74 | $5,917 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 32 | $5,634 |
| Return visit (30+ min) | 19 | $2,433 |
| Short return visit (20+ min) | 13 | $1,171 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 187 | $16,989 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 26 | $15,270 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 172 | $11,307 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 12 | $7,592 |
| 1ST HOSP IP/OBS HIGH 75 | 32 | $5,711 |
| Return visit (30+ min) | 47 | $4,553 |
2019
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 54 | $29,002 |
| Return visit (30+ min) | 233 | $23,272 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 43 | $17,948 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 204 | $17,334 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 197 | $12,818 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 42 | $12,629 |
| Return visit (30+ min) | 168 | $6,217 |
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist | 24 | $5,664 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 135 | $4,836 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 20 | $4,083 |
| 1ST HOSP IP/OBS HIGH 75 | 28 | $3,758 |
Drugs they prescribed that Part D paid
$524,924
Pharmacies billed $524,924 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
344 generic and 428 brand-name prescriptions · $524,924 in drug cost · 25 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xywav | 16 | $109,724 | $6,858 |
| Trelegy Ellipta | 84 | $85,540 | $1,018 |
| Ambrisentan | 11 | $73,300 | $6,664 |
| Breo Ellipta | 105 | $53,296 | $508 |
| Breztri Aerosphere | 28 | $17,582 | $628 |
See all 22 drugs
| Xywav | 16 | $109,724 | $6,858 |
| Trelegy Ellipta | 84 | $85,540 | $1,018 |
| Ambrisentan | 11 | $73,300 | $6,664 |
| Breo Ellipta | 105 | $53,296 | $508 |
| Breztri Aerosphere | 28 | $17,582 | $628 |
| Sunosi | 12 | $16,844 | $1,404 |
| Spiriva Respimat | 24 | $15,187 | $633 |
| Stiolto Respimat | 18 | $12,254 | $681 |
| Combivent Respimat | 13 | $6,212 | $478 |
| Symbicort | 19 | $4,828 | $254 |
| Advair Diskus | 13 | $2,568 | $198 |
| Albuterol Sulfate Hfa | 74 | $2,332 | $32 |
| Breyna | 12 | $1,694 | $141 |
| Modafinil | 20 | $1,456 | $73 |
| Eszopiclone | 21 | $752 | $36 |
| Ipratropium | 29 | $604 | $21 |
| Montelukast | 34 | $523 | $15 |
| Omeprazole | 19 | $296 | $16 |
| Azithromycin | 13 | $106 | $8 |
| Trazodone | 12 | $75 | $6 |
| Prednisone | 21 | $61 | $3 |
| Temazepam | 11 | $36 | $3 |
Year by year
| 2024 | 772 | 184 | None | 55% | $524,924 |
| 2023 | 625 | 135 | 0% (0) | 66% | $521,491 |
| 2022 | 724 | 173 | None | 58% | $608,582 |
| 2021 | 882 | 164 | 0% (0) | 56% | $449,430 |
| 2020 | 843 | 153 | None | 54% | $273,835 |
| 2019 | 908 | 169 | None | 61% | $324,868 |
| 2018 | 1,097 | 188 | None | 57% | $375,242 |
| 2017 | 799 | 141 | None | 46% | $315,432 |
| 2016 | 625 | 94 | None | 51% | $296,377 |
| 2015 | 655 | 97 | 0% (0) | 66% | $432,372 |
| 2014 | 787 | 146 | 0% (0) | 58% | $392,724 |
| 2013 | 1,278 | 163 | None | 63% | $552,530 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Ofev | 12 | $144,567 | $12,047 |
| Trelegy Ellipta | 115 | $104,511 | $909 |
| Xywav | 14 | $88,976 | $6,355 |
| Breo Ellipta | 105 | $58,237 | $555 |
| Ambrisentan | 12 | $33,995 | $2,833 |
| Stiolto Respimat | 18 | $14,313 | $795 |
| Modafinil | 17 | $7,841 | $461 |
| Anoro Ellipta | 11 | $7,763 | $706 |
| Combivent Respimat | 13 | $6,674 | $513 |
| Fluticasone-Vilanterol | 12 | $4,345 | $362 |
| Albuterol Sulfate Hfa | 47 | $2,851 | $61 |
| Ventolin Hfa | 29 | $2,567 | $89 |
| Wixela Inhub | 11 | $1,657 | $151 |
| Eszopiclone | 11 | $514 | $47 |
| Montelukast | 20 | $507 | $25 |
| Ropinirole | 13 | $322 | $25 |
| Prednisone | 19 | $106 | $6 |
2022: 18 drugs
| Ofev | 20 | $252,745 | $12,637 |
| Trelegy Ellipta | 128 | $100,843 | $788 |
| Xywav | 14 | $84,696 | $6,050 |
| Breo Ellipta | 76 | $43,472 | $572 |
| Stiolto Respimat | 35 | $20,907 | $597 |
| Xarelto | 13 | $14,276 | $1,098 |
| Symbicort | 13 | $9,406 | $724 |
| Albuterol Sulfate Hfa | 65 | $3,347 | $51 |
| Wixela Inhub | 12 | $1,863 | $155 |
| Modafinil | 14 | $1,494 | $107 |
| Eszopiclone | 28 | $864 | $31 |
| Ropinirole | 41 | $681 | $17 |
| Cefepime | 11 | $489 | $44 |
| Montelukast | 22 | $412 | $19 |
| Trazodone | 18 | $212 | $12 |
| Prednisone | 19 | $175 | $9 |
| Fluticasone Propionate | 12 | $150 | $12 |
| Zolpidem | 14 | $145 | $10 |
2021: 22 drugs
| Trelegy Ellipta | 78 | $60,375 | $774 |
| Breo Ellipta | 114 | $56,798 | $498 |
| Stiolto Respimat | 31 | $19,737 | $637 |
| Spiriva Respimat | 26 | $17,503 | $673 |
| Symbicort | 25 | $17,376 | $695 |
| Anoro Ellipta | 17 | $15,727 | $925 |
| Xarelto | 11 | $8,603 | $782 |
| Horizant | 11 | $5,169 | $470 |
| Albuterol Sulfate Hfa | 82 | $4,828 | $59 |
| Modafinil | 13 | $2,740 | $211 |
| Ventolin Hfa | 24 | $2,638 | $110 |
| Eszopiclone | 25 | $1,209 | $48 |
| Ropinirole | 61 | $804 | $13 |
| Levalbuterol Tartrate Hfa | 13 | $706 | $54 |
| Omeprazole | 20 | $603 | $30 |
| Trazodone | 39 | $500 | $13 |
| Levetiracetam-Nacl | 11 | $415 | $38 |
| Montelukast | 21 | $338 | $16 |
| Fluticasone Propionate | 15 | $224 | $15 |
| Zolpidem | 25 | $221 | $9 |
| Pantoprazole | 11 | $207 | $19 |
| Prednisone | 25 | $173 | $7 |
2020: 22 drugs
| Trelegy Ellipta | 78 | $51,001 | $654 |
| Breo Ellipta | 68 | $36,960 | $544 |
| Stiolto Respimat | 43 | $23,115 | $538 |
| Symbicort | 35 | $22,003 | $629 |
| Anoro Ellipta | 16 | $11,966 | $748 |
| Spiriva Respimat | 16 | $8,527 | $533 |
| Horizant | 11 | $5,033 | $458 |
| Ventolin Hfa | 37 | $3,304 | $89 |
| Albuterol Sulfate Hfa | 54 | $3,164 | $59 |
| Proair Hfa | 17 | $2,291 | $135 |
| Modafinil | 18 | $1,571 | $87 |
| Eszopiclone | 22 | $828 | $38 |
| Ropinirole | 38 | $599 | $16 |
| Montelukast | 24 | $373 | $16 |
| Fluticasone Propionate | 18 | $292 | $16 |
| Cefepime | 11 | $225 | $20 |
| Trazodone | 20 | $201 | $10 |
| Atorvastatin | 13 | $188 | $14 |
| Zolpidem | 23 | $126 | $5 |
| Clonazepam | 14 | $88 | $6 |
| Prednisone | 21 | $86 | $4 |
| Levofloxacin | 12 | $55 | $5 |
2019: 24 drugs
| Trelegy Ellipta | 87 | $47,921 | $551 |
| Breo Ellipta | 64 | $31,388 | $490 |
| Spiriva Respimat | 55 | $30,338 | $552 |
| Anoro Ellipta | 46 | $22,177 | $482 |
| Stiolto Respimat | 42 | $20,990 | $500 |
| Symbicort | 32 | $18,109 | $566 |
| Spiriva | 14 | $14,518 | $1,037 |
| Advair Diskus | 17 | $9,011 | $530 |
| Modafinil | 24 | $5,717 | $238 |
| Horizant | 12 | $5,106 | $425 |
| Ventolin Hfa | 56 | $3,773 | $67 |
| Proair Hfa | 28 | $2,985 | $107 |
| Dymista | 12 | $2,907 | $242 |
| Albuterol Sulfate Hfa | 48 | $2,379 | $50 |
| Ropinirole | 34 | $658 | $19 |
| Eszopiclone | 18 | $657 | $37 |
| Montelukast | 31 | $440 | $14 |
| Trazodone | 43 | $385 | $9 |
| Prednisone | 46 | $318 | $7 |
| Omeprazole | 11 | $282 | $26 |
| Clonazepam | 22 | $171 | $8 |
| Zolpidem | 20 | $127 | $6 |
| Azithromycin | 11 | $90 | $8 |
| Temazepam | 17 | $81 | $5 |
2018: 29 drugs
| Breo Ellipta | 129 | $49,062 | $380 |
| Spiriva Respimat | 67 | $30,054 | $449 |
| Advair Diskus | 50 | $24,989 | $500 |
| Symbicort | 25 | $18,016 | $721 |
| Stiolto Respimat | 37 | $17,573 | $475 |
| Spiriva | 26 | $15,545 | $598 |
| Anoro Ellipta | 33 | $14,089 | $427 |
| Incruse Ellipta | 12 | $5,253 | $438 |
| Horizant | 11 | $4,611 | $419 |
| Ventolin Hfa | 71 | $4,332 | $61 |
| Combivent Respimat | 11 | $4,147 | $377 |
| Daliresp | 11 | $3,814 | $347 |
| Methylphenidate Er | 12 | $2,918 | $243 |
| Proair Hfa | 32 | $2,497 | $78 |
| Ethambutol | 21 | $1,623 | $77 |
| Xopenex Hfa | 22 | $1,543 | $70 |
| Azelastine | 14 | $1,400 | $100 |
| Rifampin | 21 | $1,260 | $60 |
| Temazepam | 19 | $993 | $52 |
| Ropinirole | 53 | $912 | $17 |
| Eszopiclone | 25 | $817 | $33 |
| Azithromycin | 41 | $675 | $16 |
| Trazodone | 50 | $612 | $12 |
| Prednisone | 53 | $536 | $10 |
| Omeprazole | 21 | $418 | $20 |
| Montelukast | 21 | $319 | $15 |
| Digoxin | 11 | $269 | $24 |
| Zolpidem | 14 | $139 | $10 |
| Clonazepam | 19 | $136 | $7 |
2017: 21 drugs
| Letairis | 13 | $125,445 | $9,650 |
| Adcirca | 18 | $67,031 | $3,724 |
| Breo Ellipta | 72 | $26,206 | $364 |
| Spiriva | 45 | $20,039 | $445 |
| Symbicort | 27 | $9,540 | $353 |
| Advair Diskus | 24 | $9,060 | $377 |
| Tudorza Pressair | 13 | $4,394 | $338 |
| Anoro Ellipta | 12 | $4,327 | $361 |
| Dulera | 12 | $3,485 | $290 |
| Methylphenidate Er | 11 | $2,771 | $252 |
| Ventolin Hfa | 30 | $1,811 | $60 |
| Eszopiclone | 39 | $1,446 | $37 |
| Ropinirole | 86 | $1,125 | $13 |
| Rifampin | 15 | $984 | $66 |
| Azelastine | 11 | $975 | $89 |
| Azithromycin | 52 | $695 | $13 |
| Trazodone | 57 | $489 | $9 |
| Prednisone | 58 | $361 | $6 |
| Montelukast | 12 | $250 | $21 |
| Clonazepam | 26 | $141 | $5 |
| Zolpidem | 16 | $116 | $7 |
2016: 19 drugs
| Letairis | 12 | $105,356 | $8,780 |
| Adcirca | 25 | $94,134 | $3,765 |
| Spiriva | 49 | $17,479 | $357 |
| Breo Ellipta | 49 | $16,662 | $340 |
| Advair Diskus | 29 | $12,554 | $433 |
| Symbicort | 16 | $6,356 | $397 |
| Anoro Ellipta | 16 | $5,068 | $317 |
| Tudorza Pressair | 15 | $3,984 | $266 |
| Eszopiclone | 42 | $2,637 | $63 |
| Azelastine | 13 | $1,625 | $125 |
| Proair Hfa | 23 | $1,408 | $61 |
| Ventolin Hfa | 21 | $1,391 | $66 |
| Ropinirole | 64 | $1,227 | $19 |
| Azithromycin | 19 | $459 | $24 |
| Omeprazole | 21 | $345 | $16 |
| Prednisone | 28 | $239 | $9 |
| Trazodone | 18 | $227 | $13 |
| Zolpidem | 22 | $211 | $10 |
| Clonazepam | 30 | $167 | $6 |
2015: 18 drugs
| Adcirca | 69 | $180,236 | $2,612 |
| Letairis | 20 | $152,521 | $7,626 |
| Spiriva | 91 | $31,342 | $344 |
| Advair Diskus | 40 | $13,843 | $346 |
| Symbicort | 24 | $8,606 | $359 |
| Tudorza Pressair | 23 | $6,600 | $287 |
| Anoro Ellipta | 16 | $4,807 | $300 |
| Nasonex | 21 | $4,376 | $208 |
| Eszopiclone | 32 | $2,336 | $73 |
| Proair Hfa | 46 | $2,272 | $49 |
| Methylphenidate Er | 11 | $1,839 | $167 |
| Azelastine | 15 | $944 | $63 |
| Ropinirole | 45 | $826 | $18 |
| Omeprazole | 27 | $548 | $20 |
| Zolpidem | 25 | $179 | $7 |
| Azithromycin | 12 | $163 | $14 |
| Clonazepam | 13 | $83 | $6 |
| Prednisone | 14 | $67 | $5 |
2014: 18 drugs
| Letairis | 20 | $144,079 | $7,204 |
| Adcirca | 60 | $124,522 | $2,075 |
| Spiriva | 128 | $44,585 | $348 |
| Advair Diskus | 60 | $26,656 | $444 |
| Symbicort | 29 | $8,019 | $277 |
| Tudorza Pressair | 27 | $7,172 | $266 |
| Eszopiclone | 23 | $5,263 | $229 |
| Nasonex | 17 | $2,797 | $165 |
| Proair Hfa | 22 | $1,079 | $49 |
| Ropinirole | 45 | $914 | $20 |
| Omeprazole | 34 | $715 | $21 |
| Ventolin Hfa | 14 | $703 | $50 |
| Fluticasone Propionate | 18 | $328 | $18 |
| Azithromycin | 21 | $315 | $15 |
| Zolpidem | 28 | $286 | $10 |
| Prednisone | 36 | $279 | $8 |
| Clonazepam | 41 | $197 | $5 |
| Temazepam | 17 | $120 | $7 |
2013: 27 drugs
| Letairis | 33 | $222,159 | $6,732 |
| Adcirca | 78 | $132,577 | $1,700 |
| Spiriva | 221 | $69,930 | $316 |
| Advair Diskus | 155 | $54,732 | $353 |
| Symbicort | 50 | $14,040 | $281 |
| Tudorza Pressair | 29 | $6,560 | $226 |
| Dulera | 16 | $5,487 | $343 |
| Nasonex | 32 | $4,474 | $140 |
| Proair Hfa | 43 | $2,570 | $60 |
| Omeprazole | 95 | $2,541 | $27 |
| Methylphenidate Er | 12 | $2,203 | $184 |
| Foradil | 11 | $2,193 | $199 |
| Albuterol Sulfate | 12 | $1,701 | $142 |
| Azelastine | 16 | $1,687 | $105 |
| Temazepam | 21 | $1,399 | $67 |
| Xopenex Hfa | 21 | $1,307 | $62 |
| Montelukast | 20 | $1,023 | $51 |
| Ventolin Hfa | 22 | $876 | $40 |
| Azithromycin | 42 | $816 | $19 |
| Ropinirole | 38 | $750 | $20 |
| Fluticasone Propionate | 14 | $528 | $38 |
| Prednisone | 72 | $338 | $5 |
| Clonazepam | 54 | $312 | $6 |
| Pantoprazole | 14 | $291 | $21 |
| Azathioprine | 11 | $226 | $21 |
| Furosemide | 19 | $208 | $11 |
| Zolpidem | 25 | $162 | $6 |
Money from drug and device companies
$639 in 2025
| 2025 | 7 | 21 | None | $639 |
| 2024 | 5 | 6 | None | $157 |
| 2023 | 4 | 6 | None | $463 |
| 2022 | 8 | 8 | None | $206 |
| 2021 | 4 | 6 | None | $214 |
| 2020 | 3 | 4 | None | $96 |
| 2019 | 7 | 10 | None | $426 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $255 | 8 payments
|
| Jazz Pharmaceuticals | Xywav | $126 | 2 payments
|
| Insmed | Arikayce | $105 | 5 payments
|
| Lilly USA | Zepbound | $49 | 2 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $40 | 1 payment
|
| Axsome Therapeutics | Sunosi | $39 | 2 payments
|
See all 21 published payments
| Insmed | Meals · 2025-12-18 | Arikayce | $20 |
| Axsome Therapeutics | Meals · 2025-12-03 | Sunosi | $21 |
| Jazz Pharmaceuticals | Education · 2025-11-12 | Xywav | $90 |
| Jazz Pharmaceuticals | Meals · 2025-11-12 | Xywav | $36 |
| GlaxoSmithKline | Meals · 2025-11-06 | Nucala | $21 |
| Lilly USA | Meals · 2025-10-03 | Zepbound | $17 |
| Insmed | Meals · 2025-09-02 | Arikayce | $27 |
| Avadel CNS Pharmaceuticals | Meals · 2025-07-31 | Lumryz | $40 |
| GlaxoSmithKline | Meals · 2025-07-15 | Nucala | $125 |
| GlaxoSmithKline | Meals · 2025-06-17 | Trelegy Ellipta | $19 |
| GlaxoSmithKline | Meals · 2025-05-29 | Nucala | $3 |
| GlaxoSmithKline | Meals · 2025-05-28 | Nucala | $32 |
| Lilly USA | Meals · 2025-05-20 | Zepbound | $33 |
| Insmed | Meals · 2025-05-08 | Arikayce | $23 |
| Insmed | Meals · 2025-04-02 | Arikayce | $18 |
| Baxter Healthcare | Meals · 2025-03-07 | None | $25 |
| Insmed | Meals · 2025-02-24 | Arikayce | $16 |
| Axsome Therapeutics | Meals · 2025-02-11 | Sunosi | $18 |
| GlaxoSmithKline | Meals · 2025-02-07 | Trelegy Ellipta | $27 |
| GlaxoSmithKline | Meals · 2025-02-04 | Nucala | $3 |
| GlaxoSmithKline | Meals · 2025-02-03 | Nucala | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $157
| GlaxoSmithKline | Nucala | $54 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $31 | 1 payment
|
| Inspire Medical Systems | Inspire | $30 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $26 | 1 payment
|
| Insmed | Arikayce | $16 | 1 payment
|
2023: $463
| Intuitive Surgical | Da Vinci Surgical System | $356 | 3 payments
|
| Harmony Biosciences | Wakix | $60 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $24 | 1 payment
|
| Philips Electronics North America | (8874) Incourage | $23 | 1 payment
|
2022: $206
| Harmony Biosciences | Wakix | $46 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $32 | 1 payment
|
| GlaxoSmithKline | Nucala | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $22 | 1 payment
|
| Philips Electronics North America | (7999) Src Und | $21 | 1 payment
|
| LivaNova USA | Lifesparc | $20 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $16 | 1 payment
|
2021: $214
| AstraZeneca Pharmaceuticals LP | Farxiga | $130 | 2 payments
|
| Insmed | Arikayce | $44 | 2 payments
|
| United Therapeutics | Tyvaso | $24 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $15 | 1 payment
|
2020: $96
| Harmony Biosciences | Wakix | $58 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $26 | 1 payment
|
| GlaxoSmithKline | Anoro Ellipta | $12 | 1 payment
|
2019: $426
| Inspire Medical Systems | Inspire Upper Airway Stimulation System | $130 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $124 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $78 | 1 payment
|
| Medical Graphics | None | $57 | 1 payment
|
| Pfizer | Eliquis | $14 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $11 | 1 payment
|
| Gilead Sciences | None | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Roche Cancer Screening Collection Study · 2024 | Their institution | $71,462 |
| Genentech, Inc. · Roche Cancer Screening Collection Study · 2025 | Their institution | $23,522 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1447281704
- Licence
- CA A61991California A61991: Current · expires 2027-04-30
- Group
- West Coast Critical Care Specialists, Inc. · Gila River Health Care Corporation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A619910
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RS0012X (207RS0012X)
- Mailing address
- 1910 Outlet Center Dr, Oxnard, CA, 93036
- NPI first listed
- 2006-07-05
- NPI last updated
- 2020-11-24
- NPI record certified
- 2020-11-24
This is when the NPI record was last certified, not a medical board exam.